Akebia Therapeutics Announces Poster Presentation at ASN Kidney Week 2022
Akebia Therapeutics, Inc. (Nasdaq: AKBA) announced its participation in ASN Kidney Week 2022, taking place from November 3-6 in Orlando.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Akebia Therapeutics, Inc. (Nasdaq: AKBA) announced its participation in ASN Kidney Week 2022, taking place from November 3-6 in Orlando. The company will present a poster titled "Prevalence of Hyporesponse to Erythropoiesis-Stimulating Agents Among Medicare Patients with CKD-Related Anemia" on November 3 from 10:00 a.m. to 12:00 p.m. EDT. Attendees can visit Akebia at Booth #1721 for more information. Founded in 2007 and based in Cambridge, Massachusetts, Akebia focuses on developing therapeutics for kidney disease.
Positive
- Participation in ASN Kidney Week 2022 can enhance visibility among healthcare professionals.
- Opportunity to present research data that may provide valuable insights into kidney disease treatment.
Negative
- None.
Details
News Market Reaction – AKBA
The recorded move for AKBA in the trading session of this news was -4.06%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Oct. 21, 2022 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it will present data at the American Society of Nephrology Kidney Week 2022 (ASN Kidney Week 2022), which will take place in Orlando, November 3-6, 2022.
The poster titled, "Prevalence of Hyporesponse to Erythropoiesis-Stimulating Agents Among Medicare Patients with CKD-Related Anemia According to Absolute or Weight-Based Definitions," poster number TH-PO666, will be presented during the Anemia and Iron Metabolism session on Thursday, November 3 from 10:00 a.m. to 12:00 p.m. EDT. View the abstract here: https://www.asn-online.org/education/kidneyweek/2022/program-abstract.aspx?controlId=3769598.
ASN Kidney Week 2022 attendees can visit the Akebia Booth #1721.
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.
Akebia Therapeutics Contact
Mercedes Carrasco
mcarrasco@akebia.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/akebia-therapeutics-announces-poster-presentation-at-asn-kidney-week-2022-301655111.html
SOURCE Akebia Therapeutics
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.